What changed from existing technology?
This study looks at how common certain genetic changes are in women with advanced ovarian cancer in Malaysia, focusing on genes linked to DNA repair and cancer risk.
This is the first report on HRD and BRCA variants in ovarian cancer patients from Malaysia, particularly among multi-ethnic populations.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 2
Ovarian Cancer (EOC): first report among multi-ethnic patients. Ovarian cancer patients with homologous recombination deficiencies (HRD) exhibit specific cli
Title ↗OpenAlex author affiliations: Global Green Synergy (Malaysia)
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This study provides baseline data for understanding genetic factors in ovarian cancer among Malaysian populations, which could inform future targeted therapies.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.
Evidence and sources
View paper and author affiliations
Open original researchHomologous Recombination Deficiency (HRD) and BRCA oncogenic variants in newly diagnosed advanced Epithelial Ovarian Cancer (EOC): first report among multi-ethnic patientsBMC Cancer · Published 2026-08-24 ↗Author institutions and listed legal entities are separated; only verified exchange and ticker data is linked.